Loading...
By Kristin J. Kelley
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
The FDA has granted marketing authorization for the first direct-to-consumer test to provide information on three BRCA gene mutations associated with increased risks for breast, ovarian, and prostate cancer.
The three variants detected are most common in people of Ashkenazi Jewish descent (e.g., present in some 2% of Ashkenazi women), and are not prevalent in the general population (0–0.1% among other ethnicities).
The 23andMe Personal Genome Service Genetic Health Risk Report — which analyzes DNA using a self-collected saliva sample — reports on only 3 of about 1000 known BRCA mutations.
The test does not determine a person's overall cancer risk, the FDA notes, and should not be used in making treatment decisions.
Comment
LINK(S):
FDA news release (Free)
Background: Physician's First Watch coverage of FDA clearing 23andMe direct-to-consumer genetic test (Free)